BioCentury
ARTICLE | Clinical News

Acorda starts Fampridine-SR Phase II in MS

November 28, 2000 8:00 AM UTC

Acorda (Hawthorne, N.Y.) began U.S. Phase II testing of its Fampridine-SR nerve conduction enhancing compound in 30 multiple sclerosis (MS) patients. The product also is in Phase II testing to treat c...